| Factors associated with soil-transmitted helminths infection in Benin: Findings from the DeWorm3 study.PLoS Negl Trop Dis | PMID 34403424PMC8396766 | 2021-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of the recombinant human growth hormone in short children born small for gestational age: A randomized, multicentre, comparative phase III trial.Medicine (Baltimore) | PMID 34397702PMC8322493 | 2021-Jul-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.N Engl J Med | PMID 34320285无 PMCID | 2021-Jul-29 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.Lancet | PMID 34111416无 PMCID | 2021-Jul-24 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.J Headache Pain | PMID 34301173PMC8299690 | 2021-Jul-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.Cell | PMID 34161776PMC8179113 | 2021-Jul-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Trial of Pimavanserin in Dementia-Related Psychosis.N Engl J Med | PMID 34289275无 PMCID | 2021-Jul-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.Chin Med J (Engl) | PMID 34310400PMC8382383 | 2021-Jul-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.BMC Pulm Med | PMID 34289823PMC8293560 | 2021-Jul-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.J Clin Oncol | PMID 33513313无 PMCID | 2021-Jul-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.J Clin Oncol | PMID 33872070PMC8280089 | 2021-Jul-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Ten-year Outcomes After Drug-Eluting Stents or Bypass Surgery for Left Main Coronary Disease in Patients With and Without Diabetes Mellitus: The PRECOMBAT Extended Follow-Up Study.J Am Heart Assoc | PMID 34238026PMC8483465 | 2021-Jul-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.J Am Heart Assoc | PMID 34250817PMC8483500 | 2021-Jul-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.JAMA | PMID 34283183PMC8293025 | 2021-Jul-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies.J Clin Psychiatry | PMID 34288609无 PMCID | 2021-Jul-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.Lancet | PMID 34246358PMC8266301 | 2021-Jul-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Progesterone Treatment Does Not Decrease Serum Levels of Biomarkers of Glial and Neuronal Cell Injury in Moderate and Severe Traumatic Brain Injury Subjects: A Secondary Analysis of the Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment (ProTECT) III Trial.J Neurotrauma | PMID 33319651PMC8260894 | 2021-Jul-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-Reported Outcomes From a Phase 3 Randomized Controlled Trial Exploring Optimal Sequencing of Short-Term Androgen Deprivation Therapy With Prostate Radiation Therapy in Localized Prostate Cancer.Int J Radiat Oncol Biol Phys | PMID 33524545无 PMCID | 2021-Jul-15 | 0.95 | The study is a randomized Phase III oncology trial with a time-to-event endpoint (freedom from definitive deterioration), but the intervention is a sequencing strategy of radiation and androgen deprivation therapy, not a drug-containing regimen. The report focuses on patient-reported quality-of-life outcomes, which are secondary or exploratory endpoints in this context, not the primary/key secondary time-to-event efficacy endpoints (OS, PFS, DFS, etc.) for efficacy assessment. | 待处理 |
| Predictive Value of Neutrophils Count for Local Tumor Control After Chemoradiotherapy in Patients With Locally Advanced Pancreatic Carcinoma.Int J Radiat Oncol Biol Phys | PMID 33548338无 PMCID | 2021-Jul-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial.Clin Cancer Res | PMID 33632930PMC8282740 | 2021-Jul-15 | 0.95 | This is a primary result report from a Phase III randomized trial in advanced soft-tissue sarcoma with a drug intervention (doxorubicin). However, it is excluded because the primary and key secondary endpoints are cardiotoxicity outcomes (e.g., LVEF deterioration, cardiac AEs), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) required for the Kaplan-Meier digitization cohort. | 待处理 |
| Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.N Engl J Med | PMID 34260836无 PMCID | 2021-Jul-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.Arthritis Res Ther | PMID 34261541PMC8278683 | 2021-Jul-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study.PLoS Med | PMID 34260595PMC8279302 | 2021-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial.Respir Med | PMID 34171789无 PMCID | 2021 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Differences in Pneumococcal and Haemophilus influenzae Natural Antibody Development in Papua New Guinean Children in the First Year of Life.Front Immunol | PMID 34447389PMC8383109 | 2021 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.JCO Precis Oncol | PMID 34504990PMC8423397 | 2021 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.Clin Exp Rheumatol | PMID 34622764无 PMCID | 2021 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.Front Immunol | PMID 34659237PMC8511644 | 2021 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine.Front Immunol | PMID 34759933PMC8573262 | 2021 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Low-Dose-Rate versus High-Dose-Rate intracavitary brachytherapy in cervical cancer - Final Results of a Phase III randomized trial.Brachytherapy | PMID 34598883无 PMCID | 2021 | 0.90 | The record describes a Phase III randomized trial in cervical cancer (oncology, human) with primary time-to-event efficacy endpoints (DFS, OS). However, the intervention is intracavitary brachytherapy (a radiotherapy technique), not a drug-containing intervention. Therefore, it does not meet the drug intervention criterion. | 待处理 |
| Long-term foot outcomes following differential abatement of inflammation and osteoclastogenesis for active Charcot neuroarthropathy in diabetes mellitus.PLoS One | PMID 34748565PMC8575293 | 2021 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.Front Immunol | PMID 34858404PMC8630786 | 2021 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.PLoS One | PMID 34780478PMC8592441 | 2021 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Comparison of biosimilar Tigerase and Pulmozyme in long-term symptomatic therapy of patients with cystic fibrosis and severe pulmonary impairment (subgroup analysis of a Phase III randomized open-label clinical trial (NCT04468100)).PLoS One | PMID 34941914PMC8699637 | 2021 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Autologous Infusion of Bone Marrow and Mesenchymal Stromal Cells in Patients with Chronic Obstructive Pulmonary Disease: Phase I Randomized Clinical Trial.Int J Chron Obstruct Pulmon Dis | PMID 35002228PMC8733220 | 2021 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B.PLoS One | PMID 34972191PMC8719661 | 2021 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.Stress | PMID 42105298无 PMCID | 2026-Dec-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet | PMID 41275875无 PMCID | 2026-Dec-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of inhalational methoxyflurane, intranasal fentanyl, and intravenous morphine for treatment of prehospital acute pain in Norway (PreMeFen): a randomised, non-inferiority, three-arm, phase 3 trial.Lancet | PMID 41275876无 PMCID | 2026-Dec-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial.Lancet | PMID 41275879无 PMCID | 2026-Dec-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Ivarmacitinib in patients with moderate to severe atopic dermatitis stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial.J Dermatolog Treat | PMID 41612798无 PMCID | 2026-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed after three-dose priming in 2 months age infants: a randomized, blinded, controlled phase III clinical trial in China.Emerg Microbes Infect | PMID 41615771PMC12912230 | 2026-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized, placebo-controlled phase 3 trial evaluating safety, immunogenicity, and reactogenicity of RSVPreF3-Mat in high-risk pregnant women and their infants.Hum Vaccin Immunother | PMID 41766205PMC12959198 | 2026-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years.J Dermatolog Treat | PMID 41800601无 PMCID | 2026-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis.J Dermatolog Treat | PMID 41814992无 PMCID | 2026-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older: An observer-blinded, placebo-controlled, randomized, phase 3 trial.Hum Vaccin Immunother | PMID 42048601PMC13128023 | 2026-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.J Dermatolog Treat | PMID 42165315无 PMCID | 2026-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years.Hum Vaccin Immunother | PMID 42213900PMC13224755 | 2026-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.Hum Vaccin Immunother | PMID 42220116PMC13228934 | 2026-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.Hum Vaccin Immunother疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:AI 判定为 forest plot;Figure 3.:非 KM 图。 | PMID 42262312PMC13251518 | 2026-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |